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enzymes that regulate skin pigmentation
Melanin synthesis by melanocytes is one 
of the most important parameters regu-
lating skin pigmentation (Yamaguchi et 
al., 2007a), and more than 150 pigment 
genes have now been identified. The 
cosmetic industry has developed numer-
ous hypopigmenting (depigmenting or 
whitening) reagents to suppress melanin 
synthesis in order to meet the needs of 
customers with hyperpigmenting condi-
tions such as chloasma (melasma) and/
or ephelides (freckles) (Solano et al., 
2006). There is also a demand for hyper-
pigmenting (artificial tanning) reagents 
to treat vitiligo and other hypopigment-
ing diseases, and there are societies in 
which tanning is perceived as beautiful 
and healthy. Taking together these obser-
vations, methods of controlling melanin 
synthesis have considerable significance 
for patients with pigmentary disorders 
and in the general marketplace.
Enzymes involved in melanin synthe-
sis include tyrosinase, tyrosinase-related 
protein-1 (TYRP1), and dopachrome 
tautomerase (DCT) (Yamaguchi and 
Hearing, 2009). Among these enzymes 
in the tyrosinase family, tyrosinase 
in mammalian gene regulation, it is high-
ly likely that SNPs that alter the regula-
tion of gene expression may function at 
some distance from the target gene. This 
concept is exemplified in the context of 
melanocyte biology by recent associa-
tion studies into pigmentation regulation 
in the eye. The presence of a single SNP 
located within intron 86 of the HERC2 
gene was found to be the major determi-
nant of blue/brown eye-color phenotypes 
in humans (Sturm et al., 2008). Although 
this finding may have provided impe-
tus to investigate the role of this gene in 
melanocyte function, prior knowledge 
of melanocyte biology suggests that this 
SNP is likely to regulate the expression 
of the neighboring OCA2 gene, with its 
role already firmly established in the pro-
cess of pigmentation. 
To fully appreciate and extend these 
findings, the genetic associations and 
locus interactions of these candidate sus-
ceptibility genes must also be examined 
in the wider context of the autoimmune 
diseases that accompany vitiligo.
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nADPH:Quinone Oxidoreductase-1 
as a new Regulatory enzyme That 
Increases Melanin synthesis
Yuji Yamaguchi1, Vincent J. Hearing2, Akira Maeda1  
and Akimichi Morita1
Most hypopigmenting reagents target the inhibition of tyrosinase, the key 
enzyme involved in melanin synthesis. In this issue, Choi et al. report that 
nADPH:quinone oxidoreductase-1 (nQO1) increases melanin synthesis, 
probably via the suppression of tyrosinase degradation. Because nQO1 
was identified by comparing normally pigmented melanocytes with 
hypopigmented acral lentiginous melanoma cells, these results suggest 
various hypotheses regarding the carcinogenic origin of the latter. 
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plays the critical role in melanin syn-
thesis, and various factors, including 
the copper-transporter ATP7A, have 
the capacity to modulate its enzymat-
ic activity (Setty et al., 2008). Indeed, 
most hypopigmenting reagents are 
intended to suppress tyrosinase activ-
ity. Additionally, two variants of oculo-
cutaneous albinism in humans (OCA1A 
and OCA1B) are caused by mutations in 
tyrosinase. Tyrosinase is the rate-limiting 
enzyme that mediates hydroxylation 
of tyrosine to dopaqui none and the 
oxidation of 5,6-dihydroxyindole (DHI) 
to indole-5,6-quinone, which pro-
duces eumelanin (Figure 1). DCT is a 
tautomerase that converts dopachrome 
to DHI-2-carboxylic acid (DHICA), 
whereas TYRP1 is a DHICA oxidase that 
further stimulates eumelanin synthesis. 
Consequently, melanogenic enzymes 
that act within melanosomes are critical 
for the production of the pigmented bio-
polymer melanin.
nQo1 as an enhancer  
of tyrosinase activity
Yoon’s group has identified NADPH: 
quinone oxidoreductase-1 (NQO1) 
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by comparing hypopigmented acral 
lentiginous melanoma cells with 
their normal counterparts, pigmented 
melanocytes obtained from the back 
skin of the same patient (Choi et al., 
this issue). NQO1 is an enzyme that 
catalyzes the two-electron reduction 
and the detoxification of quinones 
(including coenzyme Q10, also known 
as ubiquinone, and p-benzoquinone) 
to broad-sense hydroquinones 
(including ubiquinol and narrowly 
defined hydroquinone, also known as 
1,4-benzenediol). The lower section of 
Figure 1 shows a representative reac-
tion for NQO1, which may play a role 
in melanin synthesis, specifically the 
conversion of dopaquinone to dopa-
chrome via leuko dopachrome. NQO1, 
one of the phase 2 enzymes, ordinar-
ily protects cells against free radical 
damage and oxidative stress. Because 
hydro quinone is a well-known hypop-
igmenting reagent, NQO1 may nega-
tively regulate skin pigmentation via an 
increased production of hydroquinone 
within melanocytes. Indeed, the authors 
demonstrate that overexpression of 
NQO1 results in a modest decrease in 
TYRP1 and microphthalmia-associated 
transcription factor (MITF, the mas-
ter regulator of skin pigmentation) at 
protein levels (Figure 2).
On the other hand, melanogenesis 
increased in concert with increasing 
levels of NQO1 in the various mela-
noma cell lines tested. Additionally, 
the inhibition of NQO1 resulted in 
a decrease in MITF, tyrosinase, and 
TYRP1 (but not DCT) at protein lev-
els in tissue culture and in a reduc-
tion in melanin pigment using a 
zebrafish model. Finally, overex-
pression of NQO1 resulted in an 
increase in tyrosinase protein and in 
its enzymatic activity, but not at the 
mRNA level in tissue culture. Choi 
et al. conclude that NQO1 positively 
regulates melanin synthesis, probably 
by stabilizing tyrosinase protein.
These findings triggered the 
authors’ interest in elucidating the 
mechanism(s) by which NQO1 
upregulates tyrosinase activity. 
Keap1 (Kelch-like ECH-associated 
protein 1) regulates the expression 
of NQO1 via Nrf2, a member of the 
NF-E2 family of nuclear basic leucine 
zipper transcription factors (Figure 2) 
(Dinkova-Kostova et al., 2002). Keap1 
binds to Nrf2, which translocates to 
the nucleus in response to carcinogens 
and oxidants, followed by activation 
of the antioxidant response element 
of the NQO1 gene. It seems likely 
that upregulated NQO1 enhances the 
expression of tyrosinase independent-
ly of its regulation by MITF, because 
NQO1 does not affect the expression 
of tyrosinase at the mRNA level or 
the expression of MITF at either the 
mRNA or the protein levels. Choi et 
al. hypothesize that NQO1 suppresses 
the ubiquitin–proteasome system that 
would normally degrade tyrosinase. 
Other factors that affect tyrosinase 
trafficking in melanocytes may be 
involved in the selective upregulation 
of tyrosinase in response to NQO1.
nQo1 as a therapeutic target  
for acral melanoma
To identify NQO1 as an enzyme that 
increases melanin synthesis, Choi 
Figure 1. Key players in melanin biosynthesis and nQo1 as an oxidoreductase that mediates 
the conversion of quinones to hydroquinones. Tyrosinase, DCT, and TYRP1 are enzymes that 
convert tyrosine (and DHI) to dopaquinone (and eumelanin), dopachrome to DHICA, and DHICA to 
eumelanin, respectively. Pheomelanin derives from dopaquinone based on the presence of cysteine. 
NQO1 is an oxidoreductase that mediates the conversion of quinones (including p-benzoquinone and 
coenzyme Q10) to hydroquinones (including narrowly defined hydroquinone and ubiquinol). DCT, 
dopachrome tautomerase; DHI, 5,6-dihydroxyindole; DHICA, 5,6-dihydroxyindole-2-carboxylic acid; 
NADPH, nicotinamide adenine dinuclueotide phosphate; NQO1, NADPH:quinone oxidoreductase-1; 
TYRP1, tyrosinase-related protein-1. Adapted from PubChem (http://pubchem.ncbi.nlm.nih.gov).
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Clinical Implications
•  NQO1 is a newly identified regulatory enzyme that increases tyrosinase 
activity, probably by suppressing its degradation.
•  Identification of a novel regulatory enzyme provides new 
pharmacologic opportunities to treat pigmentary disorders.
•  Likewise, identification of a novel enzyme may provide leads for the 
pharmacologic treatment of melanoma.
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important for studying carcinogenesis 
and metastasis by AM cells.
concluding remarks
In summary, Choi et al. (2010) have 
identified NQO1 as a new pigmenta-
tion regulatory enzyme that increases 
tyrosinase activity, probably by sup-
pressing its degradation. Future stud-
ies should elucidate the mechanism(s) 
by which AM occurs via NQO1 and/
or other factors identified in their 
microarray analyses at the gene level 
and in their proteomics analyses at the 
protein level.
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et al. used two established and high-
ly sensitive analytical approaches—
microarrays at the gene level and 
proteomics at the protein level—and 
they compared less pigmented cells 
with normally pigmented cells.
In addition to their findings con-
cerning the regulation of skin pig-
mentation, the investigators elegantly 
established an acral melanoma (AM) 
cell line, which has been reported only 
rarely (Murata et al., 2007). Because 
AM has a unique phenotype, in that 
amplifications of narrow regions of 
the genome (gains of chromosomes 
6p or 1q) are often observed in AM 
patients as compared with non-AM 
patients (Namiki et al., 2005), com-
parison with normal melanocytes may 
elucidate the mechanism(s) by which 
AM transformation occurs. Skin is het-
erogeneous (site-specifically different) 
in terms of the presence or absence 
of hair, degree of pigmentation, and 
epidermal thickness. Melanoma types 
obtained from various body sites 
reflect different characteristics; BRAF 
and N-RAS mutations are observed 
in melanomas with chronic sun-
induced damage, but they are rare 
in melanomas without chronic sun-
induced damage, in mucosal mela-
nomas, and in AMs (Curtin et al., 
2005). Even normal melanocytes are 
able to adopt different phenotypes in 
response to external stimuli such as 
dickkopf 1, an inhibitor of the Wnt/β-
catenin signaling pathway (Yamaguchi 
et al., 2007b). In that sense, the ideal 
comparisons would have been among 
primary AM cells, metastatic AM 
cells, and normal melanocytes locat-
ed between the two sites (primary 
and metastatic AM sites). However, 
Choi et al. identified NQO1 as an AM 
carcinogenic candidate; to explain 
the mechanism, they suggested that 
the loss of NQO1 in AM cells facili-
tates carcinogenesis due to the loss 
of its suppressive scavenger effect in 
the face of oxidative stress caused by 
reactive oxygen species. Other factors 
shown in Supplementary Tables 1 
and 2 of their article are potentially 
Figure 2. scheme summarizing how nQO1 regulates melanin synthesis in melanocytes. NQO1 
is regulated by ARE, which is enhanced by Nrf2. Nrf2 migrates into the nucleus from the cytoplasm, 
where it is released from Keap1 in response to various stimuli. NQO1 does not significantly 
affect the expression of MITF, TYRP1, or DCT, but it increases the catalytic activity and protein 
level of tyrosinase and thereby induces melanin synthesis. Vertical blue arrows indicate up- or 
downregulation in response to NQO1 stimulation; horizontal blue arrow indicates that NQO1 
stimulation has no effect on DCT expression. Blue labels indicate data presented by Choi et al. 
(2010). ARE, antioxidant response element; DCT, dopachrome tautomerase; Keap1, Kelch-like ECH-
associated protein-1; MITF, microphthalmia-associated transcription factor; NQO1, NADPH:quinone 
oxidoreductase-1; Nrf2, an NF-E2 family of nuclear basic leucine zipper transcription factors; TYRP1, 
tyrosinase-related protein-1.
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